The voluntary recall covers one lot of 60 mg extended-release capsules distributed to wholesalers and pharmacies across the United States.
BERKELEY HEIGHTS, N.J. — Breckenridge Pharmaceutical Inc. has voluntarily recalled one lot of propranolol hydrochloride extended-release capsules because the medication may contain metal contamination that could injure patients who take the affected capsules.
The recall applies specifically to Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, packaged in 100-count bottles. The affected bottles carry lot number PK25110035, National Drug Code 51991-817-01 and an expiration date of May 2029. Breckenridge announced the nationwide consumer-level recall Nov. 16.
The company said the recalled lot shared intermediate material suspected of being the source of metal contamination discovered in a different lot. That separate lot was not released to the market. Breckenridge did not specify the type or size of the possible metal material in the recalled capsules.
According to the company’s recall notice, use of capsules from the affected lot could potentially cause cuts to soft tissue in the mouth, esophagus, stomach or intestine. Breckenridge said it was not aware of any adverse events that had been assessed as related to the recalled product at the time of the announcement.
The affected medication was distributed nationwide to wholesalers and pharmacies between Oct. 26 and Nov. 4, according to Breckenridge. The recall involves only the identified lot of 60 mg extended-release capsules and does not, based on the company’s notice, apply to every propranolol product or every bottle distributed under the medication’s name.
Propranolol is a beta blocker used in the treatment of high blood pressure and certain other medical conditions. Because the recall is tied to a specific lot, the identifying information printed on a bottle is central to determining whether a particular supply is included.
Breckenridge instructed consumers with medication from the recalled lot to stop using that product and contact their physician or other health care provider for medical advice and replacement instructions. The company also said unused capsules from the affected lot should be returned to the pharmacy where they were obtained.
Wholesalers, pharmacies and other retailers were instructed to check their inventories for the recalled lot, quarantine affected bottles and stop distributing or dispensing them. Businesses that had sent the medication to other accounts were also directed to notify those recipients down to the retail level.
The recall is being conducted with the knowledge of the U.S. Food and Drug Administration. The FDA describes drug recalls as actions used to remove defective or potentially harmful medicines from the market or warn patients and health professionals about a potential risk.
Breckenridge said people who experience health problems that may be connected to the recalled medication should contact a health care provider. Adverse reactions and product-quality problems can also be reported through the FDA’s MedWatch program. No recall-related adverse events had been reported by Breckenridge when the company issued its notice.
Author note: Last updated November 17, 2026.